In contrast, the KEYNOTE–042 trial reported that 1st–line pembrolizumab therapy achieved a better prognosis than chemotherapy for patients with NSCLC in all subgroups (PD–L1 TPS between 1% and 20%, between 20% and 50% and at least 50%) (56). The gene discussed is CD274; the disease is non-small cell lung carcinoma.